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Abstract
Background—The co-occurrence of substance use disorder (SUD) and major depressive
disorder (MDD) is common and is often thought to impair response to antidepressant therapy.
These patients are often excluded from clinical trials, resulting in a significant knowledge gap
regarding optimal pharmacotherapy for the treatment of MDD with concurrent SUD.
Methods—In the Combining Medications to Enhance Depression Outcomes study, 665 adult
outpatients with chronic and/or recurrent MDD were prospectively treated with either
escitalopram monotherapy (escitalopram and placebo) or an antidepressant combination
(venalfaxine-XR and mirtazapine or escitalopram and bupropion-SR). Participants with MDD and
concurrent SUD (13.1%) were compared to those without SUD (86.9%) on sociodemographic and
clinical characteristics at baseline and treatment response at 12-week and 28-week endpoints.
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Results—The participants with MDD and SUD were more likely to be male and have current
suicidal thoughts/plans, and had a greater lifetime severity and number of suicide attempts, and a
higher number of concurrent Axis I disorders, particularly concurrent anxiety disorders. There
were no significant differences between the MDD with or without SUD groups in terms of dose,
time in treatment, response or remission at week 12 and 28. Furthermore, no significant
differences in response or remission rates were noted between groups on the basis of the presence
or absence of SUD and treatment assignment.
Conclusions—Although significant baseline sociodemographic and clinical differences exist,
patients with MDD and concurrent SUD are as likely to respond and remit to a single or
combination antidepressant treatment as those presenting without SUD.
Keywords
major depressive disorder; substance use disorder; dual diagnosis; combination antidepressants;
treatment outcome
INTRODUCTION
Approximately 25–30% of individuals with major depressive disorder (MDD) endorse
symptoms of concurrent substance use disorders (SUD)1 and these disorders are associated
with a substantially higher mortality rate.2 Compared to depressed patients without SUD,
those with SUD are significantly more likely to be younger, male, never married,
unemployed, without insurance, and to have lower incomes and fewer years of
schooling3,4,5,6 and are significantly more likely to have onset of MDD before age 18, a
positive family history of SUD, a history of suicide attempts, a higher current risk of suicide,
recurrent depression, atypical symptoms of depression, and more concurrent Axis I
disorders. These differences are most notable in individuals with MDD who endorse both
alcohol and drug use disorders.6
In practice, clinicians are often reticent to begin antidepressant treatment of MDD with
concurrent SUD, with the expectation that antidepressants will be ineffective or that the
depression will resolve spontaneously in most individuals if abstinence is achieved.7,8,9,10
As noted in a review by Ostacher,11 few definitive studies exist to actually guide clinicians
in managing patients presenting with MDD and co-occurring SUD. Our current knowledge
is the result of studies from two distinct populations – those seeking treatment for MDD who
have SUD and those seeking treatment for SUD noted to have depression. The studies of
those seeking treatment for SUD with co-occurring MDD dominate the literature. A meta-
analysis12 of fourteen double-blind, randomized controlled studies for the treatment of
depression in patients with SUD, indicated that the pooled effect size of antidepressant
treatment outcome was modest (i.e., 0.38).
Our recent report examined the effect of SUD on treatment outcomes in patients with MDD
participants in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
study. This study recruited a sample (N=2838) considerably larger than any previous study
mentioned above (Ns=28 to 113).12 Despite numerous baseline clinical differences, the
STAR*D study found no significant differences in response rates to citalopram between
MDD participants with and without SUD.6 Although there was nonsignificant difference in
remission rates between those with MDD (33%) compared to MDD+alcohol (36%) or MDD
+drug (28%), those MDD participants with both alcohol and drug use had significantly
lower rates of remission (22.5%) and longer time to achieve remission. In other words, those
individuals with MDD who endorsed both alcohol and drug use were 42% less likely to
achieve remission than those without SUD. When we examined the citalopram treatment
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outcomes for the MDD participants with both a concurrent anxiety disorder and SUD,13 a
somewhat different pattern emerged. Those participants with MDD+anxiety disorder+SUD
had poorer outcomes (25% remission and 43% response rates) than those with MDD-only
(40% remission and 52% response rates), suggesting that although response rates are fairly
consistent, achieving remission is a more challenging treatment issue in persons with
increased illness burden.
The Combining Medications to Enhance Depression Outcomes (CO-MED) study14 provides
a unique opportunity to examine whether treatment outcomes to either an antidepressant
medication monotherapy or antidepressant medication combination therapies among patients
with chronic and/or recurrent MDD differ by the presence or absence of comorbid SUD.
Although this study did not prospectively stratify randomization based on SUD status, the
large sample allows for exploratory outcome analysis between groups and thus, extends the
STAR*D findings. In addition to comparing depression treatment outcomes, we also
examined the sociodemographic and clinical characteristics of MDD patients with and
without comorbid SUD in order to replicate the findings from the STAR*D study and learn
more about how to better identify and clinically manage these dual diagnosed patients.
METHODS
Study Overview
This study was conducted using a large sample obtained from the CO-MED trial. CO-MED
was a 7-month, multisite, single-blind, randomized trial that compared the efficacy of
escitalopram (ESCIT) + placebo (PBO) vs. each of two different antidepressant medication
(ADM) combinations (bupropion-sustained release+escitalopram and venlafaxine-extended
release+mirtazapine) (1:1:1 ratio) as a first-step MDD treatment, including acute (12 weeks)
and long-term continuation treatment (total 28 weeks). Study details and methodology are
available elsewhere (www.co-med.org).14 A planned sample size of 660 subjects would
detect a 15% difference in remission rate between each ADM combination and ESCIT+PBO
(with an expected remission rate of 35%). This difference was viewed as sufficiently large to
impact practice because the number needed to treat would be seven (NNT=7), which
approximates the benefit of a single ADM over placebo in successful antidepressant
registration trials for MDD.15
Participants
This study was conducted according to the principals of the Declaration of Helsinki. The
study protocol and consent form were approved and overseen by the National Institute of
Mental Health Data and Safety Monitoring Board and by Institutional Review Boards at the
National Coordinating Center (The University of Texas Southwestern Medical Center at
Dallas), the University of Pittsburgh Data Coordinating Center, each participating Regional
Center and all relevant clinical sites. Prior to study entry, the study procedures, alternatives,
potential risks and benefits were explained to participants, who provided written informed
consent. Participants were recruited from six primary care and nine psychiatric care sites
across the United States.
Broad inclusion and minimal exclusion criteria (www.co-med.org) ensured a reasonably
representative participant sample. Briefly, eligibility criteria included: outpatient; 18–75
years of age; met DSM-IV TR criteria16 for either recurrent (≥1 prior major depressive
episode [MDE]) or chronic (current MDE for ≥2 years) MDD based on a clinical interview
and confirmed using a DSM-IV MDD symptom checklist completed by the clinical research
coordinator (CRC); in the index episode for ≥2 months; scored ≥16 on the 17-Item
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Hamilton Rating Scale for Depression (HRSD17);17 and did not have any psychotic illness
or bipolar disorder.
Baseline Data
Sociodemographic and clinical features were gathered at baseline and included assessment
of anxious features (>7 on the anxiety/somatization subscale of the baseline HSRD17),18
current Axis I disorders (self-report Psychiatric Diagnostic Screening Questionnaire
[PDSQ]),19,20, 21 the presence, severity, and functional impact of common general medical
comorbidities ([GMCs] a self-administered Comorbidity Questionnaire),22 sleep
disturbances, lethargy, melancholic and atypical features (specific item scores on the 30-
item Inventory of Depressive Symptomatology – Clinician-rated [IDS-C30])23,24,25 suicidal
ideation (the Concise Health Risk Tracking – Self-Report scale),26 and associated symptoms
(Concise Associated Symptom Tracking – Self-Rated scale). The Altman Self-Rating Mania
Scale27 was conducted as a safety measure to evaluate the uncommon, but adverse,
occurrence of antidepressant-induced manic symptoms in persons with unrecognized bipolar
disorder.28
Identification of SUD
The presence of SUD was defined as the presence of any drug and/or alcohol use disorder
(excluding nicotine or caffeine) in the past 6 months based on the participant’s response on
the baseline PDSQ. The PDSQ is a self-report 126-item “yes” or “no” screening instrument
that evaluates the presence or absence of thirteen DSM-IV disorders.29,30 The PDSQ is a
sensitive screening tool that has been validated against the “gold standard” diagnostic
interview, the Structured Clinical Interview for DSM-IV. The cut-off score used in this
study has been shown in an SUD population to yield sensitivities of 92.4% and 91.9% and
specificities of 71.4% and 82.4% for alcohol use disorder and drug use disorders,
respectively.31 A threshold of one or more endorsed items per diagnostic category was
selected to indicate positive symptoms of a drug use disorder and/or alcohol use disorder.32
The presence of concurrent Axis I psychiatric disorders, including SUD, was established
using PDSQ responses set at a threshold that established 90% specificity.33 With this
specificity, we can infer that 9 of 10 participants identified as endorsing SUD would have
met criteria for SUD by DSM-IV. Based on this cut-off, the sensitivity and specificity
corresponds to 85/80 for alcohol use disorders and 85/87 for drug use disorders. In addition,
the positive and negative predictive values are 27% and 98% for alcohol use disorders and
18% and 99% for drug use disorders, respectively. Based on this threshold, if a participant
was positive on the PDSQ for either drug or alcohol use disorder, they were considered to be
positive for SUD in our analyses (i.e. SUD+).
Antidepressant Treatment
A 12-week study period was chosen for the primary analysis so that (a) maximal doses could
be delivered for at least four weeks, (b) most participants whose depression could remit
would do so without an excessively long trial,34 and (c) attrition might be minimized.
Treatment and assessment visits occurred at baseline and weeks 1, 2, 4, 6, 8, 10, 12, 16, 20,
24 and 28. Dosage adjustments were guided by the CO-MED Operations Manual (available
at www.co-med.org), which utilized measurement-based care to provide personally-tailored
and vigorous dosing,35,36 with dosage adjustments based on the 16-item Quick Inventory of
Depressive Symptomatology – Clinician-rated (QIDS-C16),37 the Frequency, Intensity and
Burden of Side Effects Rating (FIBSER)38 and the measurement of participant adherence
obtained at each treatment visit.
Treatment was randomly assigned, stratified by clinical site using a Web-based
randomization system.39 Random block sizes of three and six were used to minimize the
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probability of identifying the next treatment assignment. Dosing schedules were based on
prior reports.40,41,42 Doses were increased only in the context of acceptable tolerability and
participants could exit the study if intolerable side effects occurred despite dose reduction or
treatment of side effects. Medication dosage and blinding guidelines are provided in Table 1.
Research Outcomes
The primary outcome, symptom remission, was based on the 16-item Quick Inventory of
Depressive Symptomatology – Self-Report (QIDS-SR16). Remission was ascribed a priori
based on the last two consecutive measurements obtained during the 12-week acute trial to
ensure that a single “good week” was not falsely signaling remission. At least one of these
ratings had to be <6, while the other had to be <8. If participants exited before 12 weeks,
their last two consecutive QIDS-SR16 scores were used to ascribe remission. Those who
exited before having two post-baseline measures were considered not remitted. Response
was defined as a ≥50% decrease in QIDS-SR16 score from baseline.
Participants could exit the study if they had received a maximally tolerated dose(s) for ≥4
weeks by week 8 without receiving a ≥30% reduction from baseline QIDS-C16. They could
enter continuation treatment (weeks 12–28) if they had received an acceptable benefit
(defined as a QIDS-C16 ≤9 by week 12) or if they reached a QIDS-C16 of 10–13 with
clinician and participant judging the benefit to be substantial enough to indicate a treatment
continuation. Thus, virtually all participants entering the continuation phase had at least a
40% reduction in baseline QIDS-C16.
Secondary outcomes included attrition, anxiety (the anxiety subscale of the IDS-C30),
function (Work and Social Adjustment Scale),43 quality of life (Quality of Life
Inventory),44,45 specific side effects (Systematic Assessment for Treatment-Emergent
Events–Systematic Inquiry [SAFTEE-SI]),46,47 cognitive and physical functioning
(Cognitive and Physical Functioning Questionnaire),48 and side-effect burden (FIBSER).
Statistical Analyses
Participants were grouped by the presence/absence of SUD (SUD+ and SUD- groups,
respectively). These two groups were compared regarding sociodemographic and clinical
characteristics, and antidepressant treatment outcomes. Descriptive statistics, including
measures of central tendency and dispersion, were computed for continuous data. Frequency
distributions were estimated for categorical data. The appropriate parametric (e.g., t-test) or
nonparametric test (e.g., chi-square, Wilcoxon tests) was used to assure a balanced
distribution of the sociodemographic, psychiatric and medical characteristics among
participants with and without SUD. At 12 and 28 weeks, unadjusted and adjusted outcomes
were compared among those with and without SUD using regression models. The type of
regression model varied by outcome and included linear regression, logistic regression,
ordinal logistic regression and negative binomial regression models. Potential confounders
were identified using a stepwise logistic regression model with an indicator of SUD as the
outcome and all other baseline characteristics as independent variables. Those variables that
remained in the final stepwise model were considered as potential confounders in the
adjusted models. The moderating effect of SUD on treatment was evaluated on two
outcomes, severity of depression (QIDS-SR16) and side effect burden (FIBSER), at 12 and
28 weeks. For severity of depression, a linear regression model was fit, and for side effect
burden an ordinal logistic regression model was fit. Both models included main effects for
treatment and SUD, as well as the two-way interaction between treatment and SUD. All
analyses are considered to be exploratory in nature and a type I error or a p-value <0.05 was
used as a threshold to identify statistical significance. No adjustments were made for
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multiple comparisons because this is a secondary, post-hoc exploratory, analysis and results
should be interpreted accordingly.
The percent change in QIDS-SR16 was calculated using the difference between the baseline
and last QIDS-SR16 scores, divided by the baseline QIDS-SR16 score. Logistic regression
models were developed to estimate the association of psychotropic medication use with
remission and response, after controlling for differences between regional centers and the
effect of baseline characteristics that were not balanced among those with and without SUD.
Time to first remission/response was defined as the first observed point of remission/
response based on the QIDS-SR16. With respect to the adjustment for regional center (i.e.
site), it is common practice in multi-center trials to control for site as a way of controlling
for unmeasured site differences. The cumulative proportions of each group that failed to
remit/respond by various time points was plotted using Kaplan-Meier curves, and log rank
tests were used to compare the cumulative proportions of the two groups.
RESULTS
Baseline Characteristics
From March 2008 through February 2009, the study randomized n=665 subjects (Figure 1).
One subject did not complete the baseline PDSQ, leaving 664 evaluable participants, of
whom 13.1% (n=87) screened positive for concurrent SUD (2.3% had both drug and alcohol
use disorders, 3% had drug use disorder only, and 7.8% had alcohol use disorder only).
Compared to SUD- participants, SUD+ participants were significantly more likely to be
male and more likely to have current suicidal thoughts/plans, a history of suicide attempts,
more prior suicide attempts, a greater lifetime severity of suicidality, higher self reported
mania score, increased irritability, anxiety and mania scores, less sleep disturbance, and
older age for sexual abuse (Table 2). SUD+ participants also screened positive on the PDSQ
for a higher number of concurrent Axis I psychiatric disorders —particularly concurrent
anxiety disorders (Table 3).
Outcome Measures by Presence or Absence of SUD
Treatment outcomes were similar at 12 weeks (Table 4) and 28 weeks (Table 5) between the
SUD- and SUD+ groups in terms of remission rates, response rates, and dose (maximum
dose, last dose). There was no difference between groups for time in treatment or medication
intolerance. The SUD+ group had fewer post-baseline visits attended (4.8 ±2.2 vs. 5.4 ±2.2,
p= 0.0055 at week 12; 6.9 ±3.8 vs. 7.8 ±3.7, p= 0.0187 at week 28). The only significant
difference regarding serious adverse events (SAEs) was a greater percentage of SUD+
participants having at least one psychiatric SAE during the 28-week period compared to
SUD- participants, although the absolute number was low for both groups. There were no
SAEs related to suicidal ideation requiring hospitalization.
Outcome by Presence or Absence of SUD and Antidepressant Medication
As shown in Table 6, the effect of treatment was not different between those with and
without SUD at week 12 or week 28 based on treatment group. However, at week 28 there
was a differential effect on early termination with a significantly high early termination rate
in the VEN+MIRT arm in those with SUD+ (10.1 ±9.6 vs.16.2 ±0.3; p=0.0138). Notably,
there were no significant differences between groups regarding burden of side effects
(FIBSER).
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The most important finding of this study is that despite greater lifetime suicidality and a
greater number of concurrent Axis I psychiatric disorders at baseline, the presence of
comorbid SUD in patients with chronic and/or recurrent MDD did not appear to
significantly affect treatment outcomes with either a single SSRI or combination
antidepressant medications in short- or long-term treatment periods. Our results extend and
compliment the findings from the larger STAR*D study of first level citalopram monotheray
in persons with MDD.
Curiously only 13% of the COMED participants had a concurrent SUD, which is much
lower than the 30% prevalence rate found in the STAR*D MDD sample (which also used
the PDSQ screening tool to assess for the presence of SUD).3,4 Possible reasons for this
difference likely reflect differences in study design and subject selection. Although a formal
analysis between these study samples was not conducted, the lower prevalence of concurrent
SUD in the COMED study may be related to a greater representation of women in the
COMED study (1:2.1 male:female) compared to STAR*D (1:1.7 male:female). Female
participants in both studies were less likely to have SUD than their male counterparts; thus,
effectively decreasing the population of SUD+ participants in the COMED study.
Additionally, the COMED study enrolled subjects with chronic and/or recurrent depression,
many of whom may have been counseled earlier in the course of their illness to decrease or
abstain from substances. Entering a study involving taking two medications may have
generated an unintended recruitment bias such that subjects with SUD were less likely to
consent and researchers were more cautious to recruit these subjects.
Baseline characteristics of the COMED participants were similar to those of the STAR*D
study in terms of ethnicity, employment, and levels of depressive symptom severity;
however, a greater percentage of COMED participants endorsed chronic depression,
reflecting the differences in inclusion criteria. Sociodemographically, this study supports
previous observations that participants with MDD+SUD are more likely to be male49,50,51,52
and have a greater number of concurrent Axis I psychiatric disorders.6
While depressive symptom severity and side effect burden were comparable with
antidepressant monotherapy and combination antidepressant therapy, the number of
participants having one or more psychiatric SAEs was higher in the SUD+ group at 28
weeks, although absolute numbers were low. While the difference in number of post-
baseline visits reached statistical difference, the numerical difference of less than one visit
between groups is not likely to be clinically meaningful. Although the presence of comorbid
SUD was not broadly associated with significant degrees of intolerability to three different
antidepressant treatments, the SUD+ SUD+ participants on antidepressant combination
therapy had greater rates of exit due to treatment intolerance (early termination) at 28 weeks
than did SUD+ participants on monotherapy. Similarly, higher rates of early exit were
observed in a study comparing combination treatment (sertraline + naltrexone) versus those
on monotherapy.53 While this could reflect pharmacodynamic or pharmacokinetic
differences in medication metabolism that result from substance abuse, in this study,
maximum doses for all study drugs were similar between the SUD- and SUD+ groups,
though there was a slight trend toward lower doses in the SUD+ group. Also of clinical
importance is the finding that the SUD+ group appears to be at a higher risk of planning or
making suicide attempts. The constellation of MDD, SUD and suicidality is complex with
contributions from genetic, familial and sociocultural elements.54,55,56,57,58,59 These
findings remind us that reinforcement of adherence to treatment, concern for medication
tolerability, and need for close medical follow-up in the dual diagnosed patient are a
clinically important. Clinicians need to be cognizant of the inherent risk of suicide in
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patients with MDD and SUD, and must offer adequate and timely treatment to reduce the
risk of suicide. Fortunately, our findings demonstrate that no particular antidepressant or
combination was consistently more effective regarding response, remission or side effect
profile at 12 or 28 weeks and that the presence of comorbid SUD does not lessen the
efficacy or tolerability of antidepressant mono- or combination medication treatments.
The strengths of the present study include 1) a large sample size with substantial minority
and ethnic representation, 2) recruitment from both primary care and psychiatric care
treatment settings, 3) enrollment of MDD participants from naturalistic treatment-seeking
“real-world” patient populations, including those with SUD, 4) a single-blind, randomized
design, and 5) a longer-term extended treatment phase.
Limitations of the present study include the use of a self-report screening tool to define
concurrent SUD and other Axis I disorders while MDD was diagnoses more rigorously. We
also did not gather information regarding the amounts or types of alcohol or drugs used, the
types of treatment received for SUD, and the change in substance use following treatment of
the depression. A more detailed diagnostic assessment and more detailed accounting of
concurrent treatments and outcomes for the comorbid disorders was not obtained in view of
the primary focus of the COMED study and need to limit participant burden. As such, we
cannot address whether treatment of depression affected the concurrent SUD. The lack of a
minimum period of abstinence prior to study entry did not systematically ensure that
depressive symptoms would not spontaneously remit after sufficient abstinence. Also, we
identified and examined comorbid SUD as a baseline correlate of treatment outcome to three
different therapies. Ideally, prospectively randomizing groups of MDD patients with and
without comorbid SUD to each of the three treatment groups would provide more definitive
data on efficacy and tolerability. Lastly, since the participants were recruited from a
psychiatric or primary care clinic, the results may not be generalizable to an addictions
treatment clinic.
In conclusion, our findings of equivalent response and remission rates with single agent or
combination antidepressant medication treatment in individuals who have chronic and/or
recurrent MDD with or without SUD supports an emerging and important paradigm shift in
clinical care. Namely, antidepressant medications may be equally beneficial for MDD
patients who are struggling with alcohol and/or drug addictions and for MDD patients who
are not. A study that prospectively addresses the clinical question of delaying or initiating
antidepressant medication treatment in depressed patients while awaiting abstinence is
warranted. The striking burden of suicidality imposed by the comorbidity of SUD is clear in
this and other studies, and should heighten the urgency to assertively treat depression in
patients who are also using drugs and/or alcohol. These findings may be useful for guiding
the treatment of persons with chronic and/or recurrent MDD and concurrent SUD in primary
care and psychiatric care clinics.
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Abbreviations: BUP-SR = bupropion-sustained release, ESCIT = escitalopram, PBO =
placebo, VEN-XR = venlafaxine-extended release, MIRT = mirtazapine,
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Table 1
Medication dosage guidelines and blinded conditions.




Week 2 1 tablet/d




Week 1 300 mg/d
Week 2 10 mg/d
Week 4 400 mg/db 20 mg/db




Day 4 75 mg/d
Week 1 150 mg/d
Week 2 15 mg/d
Week 4 225 mg/d 30 mg/d
Week 6 45 mg/db
Week 8 300 mg/db
Note: all medication increases were on the conditions that QIDS-C16 >5 and side effects were tolerable.
a
Participant blinded to this medication throughout the 7-month study. Research coordinators and physicians were not blinded to any medication to
maximize safety and facilitate informed flexible dosing decisions.
b
Maximum dose (bupropion SR was in divided dose).
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Table 3
Baseline co-morbidity characteristics of subjects with MDD with and without concurrent substance use
disorder
Baseline Characteristic









n (%) n (%)
Axis I Disorder (PDSQ)
   Agoraphobia 18 (20.7) 51 (8.8) χ2(1)=11.402 0.0007
   Bulimia 11 (12.6) 67 (11.6) χ2(1)=0.0776 0.7805
   Generalized anxiety 25 (28.7) 106 (18.4) χ2(1)=5.1284 0.0235
   Hypochondriasis 9 (10.3) 20 (3.5) (P)=0.006 0.0081
   Obsessive-compulsive 15 (17.2) 64 (11.1) χ2(1)=2.7275 0.0986
   Panic 12 (13.8) 52 (9.0) χ2(1)=1.9841 0.1590
   Post-traumatic stress 17 (19.5) 63 (10.9) χ2(1)=5.3033 0.0213
   Social phobia 35 (40.2) 143 (24.8) χ2(1)=9.1932 0.0024
   Somatoform 1 (1.1) 20 (3.5) (P)=0.1636 0.3410
Number of Axis 1 Disorders (PDSQ) χ2(4)=107.66 <.0001
   0 296 (51.3)
   1 27 (31.0) 132 (22.9)
   2 23 (26.4) 69 (12.0)
   3 9 (10.3) 41 (7.1)
   4+ 28 (32.2) 39 (6.8)
Medical Conditions (SCQ)
   Back pain 11 (12.8) 101 (17.5) χ2(1)=1.1845 0.2764
   Diabetes 3 (3.4) 71 (12.3) χ2(1)=5.9886 0.0144
   Heart 4 (4.6) 36 (6.2) χ2(1)=0.3598 0.5486
   Neuropsychological 2 (2.3) 16 (2.8) (P)=0.2807 1.0000
Number Medical Conditions (SCQ) χ2(3)=4.665 0.1980
   0 45 (52.3) 282 (49.0)
   1 25 (29.1) 133 (23.1)
   2 11 (12.8) 87 (15.1)
   3+ 5 (5.8) 74 (12.8)
Mean (SD) Mean (SD)
SCQ 3.0 (3.4) 3.4 (3.5) χ2(1)=1.0867 0.2972
N treated SCQ health problems 0.80 (1.20) 1.00 (1.28) χ2(1)=1.5701 0.2102
NOTE: Chi-square for continuous measures indicates Kruskal-Wallis test.
Abbreviations: PDSQ = psychiatric diagnostic screening questionnaire, SCQ = self-administered comorbidity questionnaire.
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